ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026
Current trends and future directions of artificial intelligence in lung cancer diagnosis.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most lethal malignancy worldwide, largely due to its late detection after its progression to advanced stages. Over the last decade, artificial intelligence (AI) applications have shown significant potential in transforming lung cancer diagnostics by improving the speed, accuracy, and personalization of early detection strategies. This review provides a comprehensive overview of current AI application landscape in early lung cancer diagnosis, encompassing medical imaging, histopathology, liquid biopsy, natural language processing of electronic health records, and genomic profiling. We explain how machine learning, deep learning, and transformer-based models are employed in lung cancer diagnosis, and summarize recent cutting-edge advances, including multimodal AI platforms and Food and Drug Administration (FDA)-approved computer-aided diagnosis/detection (CAD) systems. Furthermore, we evaluate the challenges that impede clinical translation, including data heterogeneity, interpretability, and privacy, and present prospective directions such as federated learning and multi-omics integration. Through a comprehensive analysis of the dynamic evolution of AI applications in oncology, we aim to inform researchers, clinicians, and policymakers about its diagnostic potential and translational relevance in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.